These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36353935)
1. The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study. Wei JW; Hao Y; Xiang J; Pu XX; Wang LP; Jiang ZS; Wu JX; Wang Q; Xu CW; Wang WX; Song ZB Neoplasma; 2022 Dec; 69(6):1437-1444. PubMed ID: 36353935 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma. Qian X; Wang Y; Liu F; Yuan Y; Fang C; Zhang X; Yuan S; Chen R; Yu B; Wang T; Yin Y; Li Y Front Immunol; 2022; 13():956982. PubMed ID: 36389780 [TBL] [Abstract][Full Text] [Related]
3. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785 [TBL] [Abstract][Full Text] [Related]
4. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798 [No Abstract] [Full Text] [Related]
5. Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma. Wei J; Xiang J; Hao Y; Si J; Gu X; Xu M; Song Z J Thorac Dis; 2023 Feb; 15(2):260-269. PubMed ID: 36910045 [TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
7. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410 [TBL] [Abstract][Full Text] [Related]
8. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109 [TBL] [Abstract][Full Text] [Related]
9. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression]. Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer]. Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161 [No Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. Zhou F; Guo H; Zhou X; Xie H; Tian T; Zhao W; Gao G; Xiong A; Wang L; Li W; Chen X; Zhang Y; Fan J; Wu F; Zhang Y; Zhou C Ther Adv Med Oncol; 2022; 14():17588359221136759. PubMed ID: 36419724 [TBL] [Abstract][Full Text] [Related]
14. Immunophenotyping of pulmonary sarcomatoid carcinoma. Ma Y; Li W; Li Z; Chen J; Wang H; Jiang T; Zhu J Front Immunol; 2022; 13():976739. PubMed ID: 36341325 [TBL] [Abstract][Full Text] [Related]
15. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas. Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161 [TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study. Wang W; Lin G; Hao Y; Guan Y; Zhang Y; Xu C; Wang Q; Wang D; Jiang Z; Cai J; Lou G; Song Z; Zhang Y Eur J Cancer; 2022 Oct; 174():21-30. PubMed ID: 35970032 [TBL] [Abstract][Full Text] [Related]
17. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related]
18. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. Hazama D; Nakahama K; Kodama H; Miyazaki A; Azuma K; Kawashima Y; Sato Y; Ito K; Shiraishi Y; Miura K; Takahama T; Oizumi S; Namba Y; Ikeda S; Yoshioka H; Tsuya A; Yasuda Y; Negi Y; Hara A; Toda M; Tachihara M JTO Clin Res Rep; 2024 Jan; 5(1):100613. PubMed ID: 38229769 [TBL] [Abstract][Full Text] [Related]
20. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer. Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L Front Immunol; 2022; 13():931429. PubMed ID: 36248782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]